Global Prokinetic Drugs Market

Prokinetic Drugs Comprehensive Study by Type (Cisapride, Domperidone, Metoclopramide, Levosulpiride, Erythromycin, Tegaserod, Mosapride Citrate, Itopride hydrochloride, Renzapride, Prucalopride), Application (Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others), Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia)), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others) Players and Region - Global Market Outlook to 2026

Prokinetic Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Prokinetic Drugs Market?

Prokinetic drugs are the medications used for the treatment of acid reflux disease. These drugs help to strengthen the lower esophageal sphincter (LES) and cause the contents of the stomach to empty faster that allows less time for acid reflux to occur. They are typically used with gastroesophageal reflux disease (GERD) or heartburn medications, such as proton pump inhibitors (PPIs) or H2 receptor blockers.

The market study is being classified by Type (Cisapride, Domperidone, Metoclopramide, Levosulpiride, Erythromycin, Tegaserod, Mosapride Citrate, Itopride hydrochloride, Renzapride and Prucalopride), by Application (Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others) and Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia)) and major geographies with country level break-up.

Johnson and Johnson (United States), Sanofi S.A. (France), Cadila Pharmaceuticals (India), Hanmi Pharm Co., Ltd. (South Korea), Kyowa Hakko Kirin Co., Ltd. (Japan), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd (Israel), Medley Pharmaceuticals Ltd (India), Sumitomo Dainippon Pharma Co., Ltd. (Japan) and Tranzyme Pharma, Inc. (United States) are some of the key players profiled in the study.

There are various companies that are operating in the new geographical regions by adopting various market growth initiatives such as mergers & acquisitions, expansions, investments, and others. There are various new market players are entering the market to capture market growth opportunities. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Prokinetic Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Prokinetic Drugs market by Type, Application and Region.

On the basis of geography, the market of Prokinetic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Gastrointestinal Diseases
  • Increase in Healthcare Expenditure
  • Development of New Diagnostic Centre and Hospitals

Market Trend
  • High Demand for Advanced Treatment Options for Chronic Diseases

Restraints
  • Serious Side Effects of the Prokinetic Drugs

Opportunities
  • Growing Number of Regulatory Approvals
  • Growth in the Healthcare Industry Worldwide
  • Increased Research and Development Activities

Challenges
  • Stringent Government Rules and Regulations


In August 2020, Johnson & Johnson has announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all-cash transaction.


Key Target Audience
Prokinetic Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Cisapride
  • Domperidone
  • Metoclopramide
  • Levosulpiride
  • Erythromycin
  • Tegaserod
  • Mosapride Citrate
  • Itopride hydrochloride
  • Renzapride
  • Prucalopride
By Application
  • Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others)
  • Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia)
By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Gastrointestinal Diseases
      • 3.2.2. Increase in Healthcare Expenditure
      • 3.2.3. Development of New Diagnostic Centre and Hospitals
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. High Demand for Advanced Treatment Options for Chronic Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prokinetic Drugs, by Type, Application, End-users, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Prokinetic Drugs (Value)
      • 5.2.1. Global Prokinetic Drugs by: Type (Value)
        • 5.2.1.1. Cisapride
        • 5.2.1.2. Domperidone
        • 5.2.1.3. Metoclopramide
        • 5.2.1.4. Levosulpiride
        • 5.2.1.5. Erythromycin
        • 5.2.1.6. Tegaserod
        • 5.2.1.7. Mosapride Citrate
        • 5.2.1.8. Itopride hydrochloride
        • 5.2.1.9. Renzapride
        • 5.2.1.10. Prucalopride
      • 5.2.2. Global Prokinetic Drugs by: Application (Value)
        • 5.2.2.1. Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others)
        • 5.2.2.2. Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia)
      • 5.2.3. Global Prokinetic Drugs by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Prokinetic Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online
        • 5.2.4.4. Others
      • 5.2.5. Global Prokinetic Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Prokinetic Drugs (Volume)
      • 5.3.1. Global Prokinetic Drugs by: Type (Volume)
        • 5.3.1.1. Cisapride
        • 5.3.1.2. Domperidone
        • 5.3.1.3. Metoclopramide
        • 5.3.1.4. Levosulpiride
        • 5.3.1.5. Erythromycin
        • 5.3.1.6. Tegaserod
        • 5.3.1.7. Mosapride Citrate
        • 5.3.1.8. Itopride hydrochloride
        • 5.3.1.9. Renzapride
        • 5.3.1.10. Prucalopride
      • 5.3.2. Global Prokinetic Drugs by: Application (Volume)
        • 5.3.2.1. Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others)
        • 5.3.2.2. Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia)
      • 5.3.3. Global Prokinetic Drugs by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global Prokinetic Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online
        • 5.3.4.4. Others
      • 5.3.5. Global Prokinetic Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Prokinetic Drugs (Price)
      • 5.4.1. Global Prokinetic Drugs by: Type (Price)
  • 6. Prokinetic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson and Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi S.A. (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cadila Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hanmi Pharm Co., Ltd. (South Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kyowa Hakko Kirin Co., Ltd. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Medley Pharmaceuticals Ltd (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sumitomo Dainippon Pharma Co., Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Tranzyme Pharma, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Prokinetic Drugs Sale, by Type, Application, End-users, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Prokinetic Drugs (Value)
      • 7.2.1. Global Prokinetic Drugs by: Type (Value)
        • 7.2.1.1. Cisapride
        • 7.2.1.2. Domperidone
        • 7.2.1.3. Metoclopramide
        • 7.2.1.4. Levosulpiride
        • 7.2.1.5. Erythromycin
        • 7.2.1.6. Tegaserod
        • 7.2.1.7. Mosapride Citrate
        • 7.2.1.8. Itopride hydrochloride
        • 7.2.1.9. Renzapride
        • 7.2.1.10. Prucalopride
      • 7.2.2. Global Prokinetic Drugs by: Application (Value)
        • 7.2.2.1. Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others)
        • 7.2.2.2. Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia)
      • 7.2.3. Global Prokinetic Drugs by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Prokinetic Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online
        • 7.2.4.4. Others
      • 7.2.5. Global Prokinetic Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Prokinetic Drugs (Volume)
      • 7.3.1. Global Prokinetic Drugs by: Type (Volume)
        • 7.3.1.1. Cisapride
        • 7.3.1.2. Domperidone
        • 7.3.1.3. Metoclopramide
        • 7.3.1.4. Levosulpiride
        • 7.3.1.5. Erythromycin
        • 7.3.1.6. Tegaserod
        • 7.3.1.7. Mosapride Citrate
        • 7.3.1.8. Itopride hydrochloride
        • 7.3.1.9. Renzapride
        • 7.3.1.10. Prucalopride
      • 7.3.2. Global Prokinetic Drugs by: Application (Volume)
        • 7.3.2.1. Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others)
        • 7.3.2.2. Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia)
      • 7.3.3. Global Prokinetic Drugs by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global Prokinetic Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online
        • 7.3.4.4. Others
      • 7.3.5. Global Prokinetic Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Prokinetic Drugs (Price)
      • 7.4.1. Global Prokinetic Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prokinetic Drugs: by Type(USD Million)
  • Table 2. Prokinetic Drugs Cisapride , by Region USD Million (2015-2020)
  • Table 3. Prokinetic Drugs Domperidone , by Region USD Million (2015-2020)
  • Table 4. Prokinetic Drugs Metoclopramide , by Region USD Million (2015-2020)
  • Table 5. Prokinetic Drugs Levosulpiride , by Region USD Million (2015-2020)
  • Table 6. Prokinetic Drugs Erythromycin , by Region USD Million (2015-2020)
  • Table 7. Prokinetic Drugs Tegaserod , by Region USD Million (2015-2020)
  • Table 8. Prokinetic Drugs Mosapride Citrate , by Region USD Million (2015-2020)
  • Table 9. Prokinetic Drugs Itopride hydrochloride , by Region USD Million (2015-2020)
  • Table 10. Prokinetic Drugs Renzapride , by Region USD Million (2015-2020)
  • Table 11. Prokinetic Drugs Prucalopride , by Region USD Million (2015-2020)
  • Table 12. Prokinetic Drugs: by Application(USD Million)
  • Table 13. Prokinetic Drugs Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others) , by Region USD Million (2015-2020)
  • Table 14. Prokinetic Drugs Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia) , by Region USD Million (2015-2020)
  • Table 15. Prokinetic Drugs: by End-users(USD Million)
  • Table 16. Prokinetic Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 17. Prokinetic Drugs Clinics , by Region USD Million (2015-2020)
  • Table 18. Prokinetic Drugs Others , by Region USD Million (2015-2020)
  • Table 19. Prokinetic Drugs: by Distribution Channel(USD Million)
  • Table 20. Prokinetic Drugs Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 21. Prokinetic Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 22. Prokinetic Drugs Online , by Region USD Million (2015-2020)
  • Table 23. Prokinetic Drugs Others , by Region USD Million (2015-2020)
  • Table 24. South America Prokinetic Drugs, by Country USD Million (2015-2020)
  • Table 25. South America Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 26. South America Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 27. South America Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 28. South America Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 29. Brazil Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 30. Brazil Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 31. Brazil Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 32. Brazil Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 33. Argentina Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 34. Argentina Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 35. Argentina Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 36. Argentina Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 37. Rest of South America Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 39. Rest of South America Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 40. Rest of South America Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 41. Asia Pacific Prokinetic Drugs, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 43. Asia Pacific Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 44. Asia Pacific Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 45. Asia Pacific Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 46. China Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 47. China Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 48. China Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 49. China Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 50. Japan Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 51. Japan Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 52. Japan Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 53. Japan Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. India Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 55. India Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 56. India Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 57. India Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 58. South Korea Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 59. South Korea Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 60. South Korea Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 61. South Korea Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 62. Taiwan Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 63. Taiwan Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 64. Taiwan Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 65. Taiwan Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 66. Australia Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 67. Australia Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 68. Australia Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 69. Australia Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 74. Europe Prokinetic Drugs, by Country USD Million (2015-2020)
  • Table 75. Europe Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 76. Europe Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 77. Europe Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 78. Europe Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. Germany Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 80. Germany Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 81. Germany Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 82. Germany Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 83. France Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 84. France Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 85. France Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 86. France Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 87. Italy Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 88. Italy Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 89. Italy Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 90. Italy Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 91. United Kingdom Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 92. United Kingdom Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 93. United Kingdom Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 94. United Kingdom Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 95. Netherlands Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 96. Netherlands Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 97. Netherlands Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 98. Netherlands Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 99. Rest of Europe Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 100. Rest of Europe Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 101. Rest of Europe Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 102. Rest of Europe Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 103. MEA Prokinetic Drugs, by Country USD Million (2015-2020)
  • Table 104. MEA Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 105. MEA Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 106. MEA Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 107. MEA Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 108. Middle East Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 109. Middle East Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 110. Middle East Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 111. Middle East Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 112. Africa Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 113. Africa Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 114. Africa Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 115. Africa Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 116. North America Prokinetic Drugs, by Country USD Million (2015-2020)
  • Table 117. North America Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 118. North America Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 119. North America Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 120. North America Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 121. United States Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 122. United States Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 123. United States Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 124. United States Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 125. Canada Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 126. Canada Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 127. Canada Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 128. Canada Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 129. Mexico Prokinetic Drugs, by Type USD Million (2015-2020)
  • Table 130. Mexico Prokinetic Drugs, by Application USD Million (2015-2020)
  • Table 131. Mexico Prokinetic Drugs, by End-users USD Million (2015-2020)
  • Table 132. Mexico Prokinetic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 133. Prokinetic Drugs Sales: by Type(K Units)
  • Table 134. Prokinetic Drugs Sales Cisapride , by Region K Units (2015-2020)
  • Table 135. Prokinetic Drugs Sales Domperidone , by Region K Units (2015-2020)
  • Table 136. Prokinetic Drugs Sales Metoclopramide , by Region K Units (2015-2020)
  • Table 137. Prokinetic Drugs Sales Levosulpiride , by Region K Units (2015-2020)
  • Table 138. Prokinetic Drugs Sales Erythromycin , by Region K Units (2015-2020)
  • Table 139. Prokinetic Drugs Sales Tegaserod , by Region K Units (2015-2020)
  • Table 140. Prokinetic Drugs Sales Mosapride Citrate , by Region K Units (2015-2020)
  • Table 141. Prokinetic Drugs Sales Itopride hydrochloride , by Region K Units (2015-2020)
  • Table 142. Prokinetic Drugs Sales Renzapride , by Region K Units (2015-2020)
  • Table 143. Prokinetic Drugs Sales Prucalopride , by Region K Units (2015-2020)
  • Table 144. Prokinetic Drugs Sales: by Application(K Units)
  • Table 145. Prokinetic Drugs Sales Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others) , by Region K Units (2015-2020)
  • Table 146. Prokinetic Drugs Sales Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia) , by Region K Units (2015-2020)
  • Table 147. Prokinetic Drugs Sales: by End-users(K Units)
  • Table 148. Prokinetic Drugs Sales Hospitals , by Region K Units (2015-2020)
  • Table 149. Prokinetic Drugs Sales Clinics , by Region K Units (2015-2020)
  • Table 150. Prokinetic Drugs Sales Others , by Region K Units (2015-2020)
  • Table 151. Prokinetic Drugs Sales: by Distribution Channel(K Units)
  • Table 152. Prokinetic Drugs Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 153. Prokinetic Drugs Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 154. Prokinetic Drugs Sales Online , by Region K Units (2015-2020)
  • Table 155. Prokinetic Drugs Sales Others , by Region K Units (2015-2020)
  • Table 156. South America Prokinetic Drugs Sales, by Country K Units (2015-2020)
  • Table 157. South America Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 158. South America Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 159. South America Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 160. South America Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 161. Brazil Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 162. Brazil Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 163. Brazil Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 164. Brazil Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 165. Argentina Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 166. Argentina Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 167. Argentina Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 168. Argentina Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 169. Rest of South America Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 170. Rest of South America Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 171. Rest of South America Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 172. Rest of South America Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. Asia Pacific Prokinetic Drugs Sales, by Country K Units (2015-2020)
  • Table 174. Asia Pacific Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 175. Asia Pacific Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 176. Asia Pacific Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 177. Asia Pacific Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 178. China Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 179. China Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 180. China Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 181. China Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 182. Japan Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 183. Japan Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 184. Japan Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 185. Japan Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 186. India Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 187. India Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 188. India Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 189. India Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 190. South Korea Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 191. South Korea Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 192. South Korea Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 193. South Korea Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 194. Taiwan Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 195. Taiwan Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 196. Taiwan Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 197. Taiwan Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 198. Australia Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 199. Australia Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 200. Australia Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 201. Australia Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 202. Rest of Asia-Pacific Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 203. Rest of Asia-Pacific Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 204. Rest of Asia-Pacific Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 205. Rest of Asia-Pacific Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 206. Europe Prokinetic Drugs Sales, by Country K Units (2015-2020)
  • Table 207. Europe Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 208. Europe Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 209. Europe Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 210. Europe Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 211. Germany Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 212. Germany Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 213. Germany Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 214. Germany Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 215. France Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 216. France Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 217. France Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 218. France Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 219. Italy Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 220. Italy Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 221. Italy Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 222. Italy Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 223. United Kingdom Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 224. United Kingdom Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 225. United Kingdom Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 226. United Kingdom Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 227. Netherlands Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 228. Netherlands Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 229. Netherlands Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 230. Netherlands Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 231. Rest of Europe Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 232. Rest of Europe Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 233. Rest of Europe Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 234. Rest of Europe Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 235. MEA Prokinetic Drugs Sales, by Country K Units (2015-2020)
  • Table 236. MEA Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 237. MEA Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 238. MEA Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 239. MEA Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 240. Middle East Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 241. Middle East Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 242. Middle East Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 243. Middle East Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 244. Africa Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 245. Africa Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 246. Africa Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 247. Africa Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 248. North America Prokinetic Drugs Sales, by Country K Units (2015-2020)
  • Table 249. North America Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 250. North America Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 251. North America Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 252. North America Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 253. United States Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 254. United States Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 255. United States Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 256. United States Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 257. Canada Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 258. Canada Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 259. Canada Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 260. Canada Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 261. Mexico Prokinetic Drugs Sales, by Type K Units (2015-2020)
  • Table 262. Mexico Prokinetic Drugs Sales, by Application K Units (2015-2020)
  • Table 263. Mexico Prokinetic Drugs Sales, by End-users K Units (2015-2020)
  • Table 264. Mexico Prokinetic Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 265. Prokinetic Drugs: by Type(USD/Units)
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Prokinetic Drugs: by Type(USD Million)
  • Table 277. Prokinetic Drugs Cisapride , by Region USD Million (2021-2026)
  • Table 278. Prokinetic Drugs Domperidone , by Region USD Million (2021-2026)
  • Table 279. Prokinetic Drugs Metoclopramide , by Region USD Million (2021-2026)
  • Table 280. Prokinetic Drugs Levosulpiride , by Region USD Million (2021-2026)
  • Table 281. Prokinetic Drugs Erythromycin , by Region USD Million (2021-2026)
  • Table 282. Prokinetic Drugs Tegaserod , by Region USD Million (2021-2026)
  • Table 283. Prokinetic Drugs Mosapride Citrate , by Region USD Million (2021-2026)
  • Table 284. Prokinetic Drugs Itopride hydrochloride , by Region USD Million (2021-2026)
  • Table 285. Prokinetic Drugs Renzapride , by Region USD Million (2021-2026)
  • Table 286. Prokinetic Drugs Prucalopride , by Region USD Million (2021-2026)
  • Table 287. Prokinetic Drugs: by Application(USD Million)
  • Table 288. Prokinetic Drugs Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others) , by Region USD Million (2021-2026)
  • Table 289. Prokinetic Drugs Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia) , by Region USD Million (2021-2026)
  • Table 290. Prokinetic Drugs: by End-users(USD Million)
  • Table 291. Prokinetic Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 292. Prokinetic Drugs Clinics , by Region USD Million (2021-2026)
  • Table 293. Prokinetic Drugs Others , by Region USD Million (2021-2026)
  • Table 294. Prokinetic Drugs: by Distribution Channel(USD Million)
  • Table 295. Prokinetic Drugs Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 296. Prokinetic Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 297. Prokinetic Drugs Online , by Region USD Million (2021-2026)
  • Table 298. Prokinetic Drugs Others , by Region USD Million (2021-2026)
  • Table 299. South America Prokinetic Drugs, by Country USD Million (2021-2026)
  • Table 300. South America Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 301. South America Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 302. South America Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 303. South America Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 304. Brazil Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 305. Brazil Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 306. Brazil Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 307. Brazil Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 308. Argentina Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 309. Argentina Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 310. Argentina Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 311. Argentina Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 312. Rest of South America Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 313. Rest of South America Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 314. Rest of South America Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 315. Rest of South America Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 316. Asia Pacific Prokinetic Drugs, by Country USD Million (2021-2026)
  • Table 317. Asia Pacific Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 318. Asia Pacific Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 319. Asia Pacific Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 320. Asia Pacific Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 321. China Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 322. China Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 323. China Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 324. China Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 325. Japan Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 326. Japan Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 327. Japan Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 328. Japan Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 329. India Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 330. India Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 331. India Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 332. India Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 333. South Korea Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 334. South Korea Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 335. South Korea Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 336. South Korea Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 337. Taiwan Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 338. Taiwan Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 339. Taiwan Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 340. Taiwan Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 341. Australia Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 342. Australia Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 343. Australia Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 344. Australia Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 345. Rest of Asia-Pacific Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 346. Rest of Asia-Pacific Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 347. Rest of Asia-Pacific Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 348. Rest of Asia-Pacific Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 349. Europe Prokinetic Drugs, by Country USD Million (2021-2026)
  • Table 350. Europe Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 351. Europe Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 352. Europe Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 353. Europe Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 354. Germany Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 355. Germany Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 356. Germany Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 357. Germany Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 358. France Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 359. France Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 360. France Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 361. France Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 362. Italy Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 363. Italy Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 364. Italy Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 365. Italy Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 366. United Kingdom Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 367. United Kingdom Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 368. United Kingdom Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 369. United Kingdom Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 370. Netherlands Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 371. Netherlands Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 372. Netherlands Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 373. Netherlands Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 374. Rest of Europe Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 375. Rest of Europe Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 376. Rest of Europe Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 377. Rest of Europe Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 378. MEA Prokinetic Drugs, by Country USD Million (2021-2026)
  • Table 379. MEA Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 380. MEA Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 381. MEA Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 382. MEA Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 383. Middle East Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 384. Middle East Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 385. Middle East Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 386. Middle East Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 387. Africa Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 388. Africa Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 389. Africa Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 390. Africa Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 391. North America Prokinetic Drugs, by Country USD Million (2021-2026)
  • Table 392. North America Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 393. North America Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 394. North America Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 395. North America Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 396. United States Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 397. United States Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 398. United States Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 399. United States Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 400. Canada Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 401. Canada Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 402. Canada Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 403. Canada Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 404. Mexico Prokinetic Drugs, by Type USD Million (2021-2026)
  • Table 405. Mexico Prokinetic Drugs, by Application USD Million (2021-2026)
  • Table 406. Mexico Prokinetic Drugs, by End-users USD Million (2021-2026)
  • Table 407. Mexico Prokinetic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 408. Prokinetic Drugs Sales: by Type(K Units)
  • Table 409. Prokinetic Drugs Sales Cisapride , by Region K Units (2021-2026)
  • Table 410. Prokinetic Drugs Sales Domperidone , by Region K Units (2021-2026)
  • Table 411. Prokinetic Drugs Sales Metoclopramide , by Region K Units (2021-2026)
  • Table 412. Prokinetic Drugs Sales Levosulpiride , by Region K Units (2021-2026)
  • Table 413. Prokinetic Drugs Sales Erythromycin , by Region K Units (2021-2026)
  • Table 414. Prokinetic Drugs Sales Tegaserod , by Region K Units (2021-2026)
  • Table 415. Prokinetic Drugs Sales Mosapride Citrate , by Region K Units (2021-2026)
  • Table 416. Prokinetic Drugs Sales Itopride hydrochloride , by Region K Units (2021-2026)
  • Table 417. Prokinetic Drugs Sales Renzapride , by Region K Units (2021-2026)
  • Table 418. Prokinetic Drugs Sales Prucalopride , by Region K Units (2021-2026)
  • Table 419. Prokinetic Drugs Sales: by Application(K Units)
  • Table 420. Prokinetic Drugs Sales Gastrointestinal Symptoms (Abdominal Discomfort, Bloating, Constipation, Heart Burn and Others) , by Region K Units (2021-2026)
  • Table 421. Prokinetic Drugs Sales Gastrointestinal Disorders (Irritable Bowel Syndrome, Gastritis, Gastroparesis and Functional Dyspepsia) , by Region K Units (2021-2026)
  • Table 422. Prokinetic Drugs Sales: by End-users(K Units)
  • Table 423. Prokinetic Drugs Sales Hospitals , by Region K Units (2021-2026)
  • Table 424. Prokinetic Drugs Sales Clinics , by Region K Units (2021-2026)
  • Table 425. Prokinetic Drugs Sales Others , by Region K Units (2021-2026)
  • Table 426. Prokinetic Drugs Sales: by Distribution Channel(K Units)
  • Table 427. Prokinetic Drugs Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 428. Prokinetic Drugs Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 429. Prokinetic Drugs Sales Online , by Region K Units (2021-2026)
  • Table 430. Prokinetic Drugs Sales Others , by Region K Units (2021-2026)
  • Table 431. South America Prokinetic Drugs Sales, by Country K Units (2021-2026)
  • Table 432. South America Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 433. South America Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 434. South America Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 435. South America Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 436. Brazil Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 437. Brazil Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 438. Brazil Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 439. Brazil Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 440. Argentina Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 441. Argentina Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 442. Argentina Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 443. Argentina Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 444. Rest of South America Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 445. Rest of South America Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 446. Rest of South America Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 447. Rest of South America Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 448. Asia Pacific Prokinetic Drugs Sales, by Country K Units (2021-2026)
  • Table 449. Asia Pacific Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 450. Asia Pacific Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 451. Asia Pacific Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 452. Asia Pacific Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 453. China Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 454. China Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 455. China Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 456. China Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 457. Japan Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 458. Japan Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 459. Japan Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 460. Japan Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 461. India Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 462. India Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 463. India Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 464. India Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 465. South Korea Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 466. South Korea Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 467. South Korea Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 468. South Korea Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 469. Taiwan Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 470. Taiwan Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 471. Taiwan Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 472. Taiwan Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 473. Australia Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 474. Australia Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 475. Australia Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 476. Australia Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 477. Rest of Asia-Pacific Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 478. Rest of Asia-Pacific Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 479. Rest of Asia-Pacific Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 480. Rest of Asia-Pacific Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 481. Europe Prokinetic Drugs Sales, by Country K Units (2021-2026)
  • Table 482. Europe Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 483. Europe Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 484. Europe Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 485. Europe Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 486. Germany Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 487. Germany Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 488. Germany Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 489. Germany Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 490. France Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 491. France Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 492. France Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 493. France Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 494. Italy Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 495. Italy Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 496. Italy Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 497. Italy Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 498. United Kingdom Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 499. United Kingdom Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 500. United Kingdom Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 501. United Kingdom Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 502. Netherlands Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 503. Netherlands Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 504. Netherlands Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 505. Netherlands Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 506. Rest of Europe Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 507. Rest of Europe Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 508. Rest of Europe Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 509. Rest of Europe Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 510. MEA Prokinetic Drugs Sales, by Country K Units (2021-2026)
  • Table 511. MEA Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 512. MEA Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 513. MEA Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 514. MEA Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 515. Middle East Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 516. Middle East Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 517. Middle East Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 518. Middle East Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 519. Africa Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 520. Africa Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 521. Africa Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 522. Africa Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 523. North America Prokinetic Drugs Sales, by Country K Units (2021-2026)
  • Table 524. North America Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 525. North America Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 526. North America Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 527. North America Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 528. United States Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 529. United States Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 530. United States Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 531. United States Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 532. Canada Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 533. Canada Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 534. Canada Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 535. Canada Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 536. Mexico Prokinetic Drugs Sales, by Type K Units (2021-2026)
  • Table 537. Mexico Prokinetic Drugs Sales, by Application K Units (2021-2026)
  • Table 538. Mexico Prokinetic Drugs Sales, by End-users K Units (2021-2026)
  • Table 539. Mexico Prokinetic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 540. Prokinetic Drugs: by Type(USD/Units)
  • Table 541. Research Programs/Design for This Report
  • Table 542. Key Data Information from Secondary Sources
  • Table 543. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prokinetic Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Prokinetic Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Prokinetic Drugs: by End-users USD Million (2015-2020)
  • Figure 7. Global Prokinetic Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Prokinetic Drugs Share (%), by Country
  • Figure 9. Asia Pacific Prokinetic Drugs Share (%), by Country
  • Figure 10. Europe Prokinetic Drugs Share (%), by Country
  • Figure 11. MEA Prokinetic Drugs Share (%), by Country
  • Figure 12. North America Prokinetic Drugs Share (%), by Country
  • Figure 13. Global Prokinetic Drugs: by Type K Units (2015-2020)
  • Figure 14. Global Prokinetic Drugs: by Application K Units (2015-2020)
  • Figure 15. Global Prokinetic Drugs: by End-users K Units (2015-2020)
  • Figure 16. Global Prokinetic Drugs: by Distribution Channel K Units (2015-2020)
  • Figure 17. South America Prokinetic Drugs Share (%), by Country
  • Figure 18. Asia Pacific Prokinetic Drugs Share (%), by Country
  • Figure 19. Europe Prokinetic Drugs Share (%), by Country
  • Figure 20. MEA Prokinetic Drugs Share (%), by Country
  • Figure 21. North America Prokinetic Drugs Share (%), by Country
  • Figure 22. Global Prokinetic Drugs: by Type USD/Units (2015-2020)
  • Figure 23. Global Prokinetic Drugs share by Players 2020 (%)
  • Figure 24. Global Prokinetic Drugs share by Players (Top 3) 2020(%)
  • Figure 25. Global Prokinetic Drugs share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 29. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 31. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 32. Cadila Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 33. Hanmi Pharm Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 34. Hanmi Pharm Co., Ltd. (South Korea) Revenue: by Geography 2020
  • Figure 35. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 40. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 41. Medley Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 42. Medley Pharmaceuticals Ltd (India) Revenue: by Geography 2020
  • Figure 43. Sumitomo Dainippon Pharma Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 44. Sumitomo Dainippon Pharma Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 45. Tranzyme Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Tranzyme Pharma, Inc. (United States) Revenue: by Geography 2020
  • Figure 47. Global Prokinetic Drugs: by Type USD Million (2021-2026)
  • Figure 48. Global Prokinetic Drugs: by Application USD Million (2021-2026)
  • Figure 49. Global Prokinetic Drugs: by End-users USD Million (2021-2026)
  • Figure 50. Global Prokinetic Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 51. South America Prokinetic Drugs Share (%), by Country
  • Figure 52. Asia Pacific Prokinetic Drugs Share (%), by Country
  • Figure 53. Europe Prokinetic Drugs Share (%), by Country
  • Figure 54. MEA Prokinetic Drugs Share (%), by Country
  • Figure 55. North America Prokinetic Drugs Share (%), by Country
  • Figure 56. Global Prokinetic Drugs: by Type K Units (2021-2026)
  • Figure 57. Global Prokinetic Drugs: by Application K Units (2021-2026)
  • Figure 58. Global Prokinetic Drugs: by End-users K Units (2021-2026)
  • Figure 59. Global Prokinetic Drugs: by Distribution Channel K Units (2021-2026)
  • Figure 60. South America Prokinetic Drugs Share (%), by Country
  • Figure 61. Asia Pacific Prokinetic Drugs Share (%), by Country
  • Figure 62. Europe Prokinetic Drugs Share (%), by Country
  • Figure 63. MEA Prokinetic Drugs Share (%), by Country
  • Figure 64. North America Prokinetic Drugs Share (%), by Country
  • Figure 65. Global Prokinetic Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Johnson and Johnson (United States)
  • Sanofi S.A. (France)
  • Cadila Pharmaceuticals (India)
  • Hanmi Pharm Co., Ltd. (South Korea)
  • Kyowa Hakko Kirin Co., Ltd. (Japan)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Medley Pharmaceuticals Ltd (India)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Tranzyme Pharma, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2021 210 Pages 54 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Prokinetic Drugs Market Quantitative research analysis
Global Prokinetic Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Gastrointestinal Diseases " is seen as one of major growth factors of Prokinetic Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Prokinetic Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Womens Health Diagnostic Comprehensive Study by Type (Diagnostic Tests, Diagnostic Devices (Biopsy, Imaging, and Monitoring)), Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregn...
$ 3750
Osteoarthritis Therapeutics Comprehensive Study by Type (Primary osteoarthritis, Secondary osteoarthritis), Application (Lifestyle changes. Exercise, Pain relief medicines, Supportive treatments, Sur...
$ 3750
Arthritis Therapeutics Comprehensive Study by Application (Hospital and Healthcare, Pharmaceutical Industry), Route of Administration (Oral, Parenteral, Topical), Sales Channel (Hospital Pharmacies, ...
$ 3750
Autoimmune Hepatitis Treatment Comprehensive Study by Disease Type (Type 1 autoimmune hepatitis, Type 2 autoimmune hepatitis), Treatment (Immunosuppressant Drugs (Corticosteroids), Liver Transplant),...
$ 3750
Diabetic Foot Ulcer Treatment Comprehensive Study by Type (Wound Care Dressings (Alginate Dressings, Hydrofiber Dressings, Foam Dressings, Film Dressing, Hydrocolloid Dressings, Surgical Dressings, H...
$ 3750
Polycystic Ovarian Syndrome Treatment Comprehensive Study by Treatment (Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others), Surgery (Ovarian Wedg...
$ 3750